Two phase I trials are combining dostarlimab with other mAbs that enhance either T-cell function and PD-1 blockade activity (TSR-033; NCT03250832, 2017) or antitumor responses and immune-mediated tumor cell killing (GSK4381562; NCT05277051, 2022). Here, PDCD1 is linked to neoplasm.